The first patient has been dosed in the P-Ib trial to evaluate TT11 + BMS’ nivolumab in ~14 patients with r/r CD30+ cHL. Patients will receive 2 cycles of nivolumab given at intervals of 4wks., followed by CT that depletes lymphocytes using fludarabine/bendamustine
The 1EPs of the trial are safety & tolerability of the combination regimen & 2EPs incl. ORR, DoR & PFS. The results from the pilot part of the P-II (CHARIOT) trial for TT11 showed a favorable safety profile and promising efficacy in patients with r/r cHL, CR rate of 57.1% & ORR of 71.4%
The company plans to advance the therapy in (CHARIOT) trial in 2022 & improved an allogeneic “off-the-shelf” cell therapy platform that targets a variety of cancers and augments EBVSTs with CD30-CAR
Ref: Globe Newswire | Image: Tessa
